AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

TRISTEL PLC

Report Publication Announcement Oct 6, 2020

7990_rns_2020-10-06_74ca62cc-fc57-448c-b1b1-23114e0ff4b6.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 1504B

Tristel PLC

06 October 2020

Tristel plc

("Tristel" or the "Company")

Notice of Results

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, confirms that its preliminary results for the year ended 30 June 2020 will be announced on Monday 19 October 2020.

Due to physical distancing restrictions and to comply with UK Government directives to avoid non-essential travel, Tristel will not be hosting its usual shareholder investor presentations in the City, London. However, on Monday 19 October 2020 at 7am, a video presentation recorded by Paul Swinney, CEO and Liz Dixon, FD, will be made available here: https://www.tristelresults.com

If shareholders have any questions on the preliminary results for the management, please send them to [email protected] and the Company will address them within the confines of information already disclosed to the market. Responses of the Q&A will also be made available on the Company's website as soon as possible.

For further information please contact:       

## Tristel plc Tel: 01638 721 500
Paul Swinney, Chief Executive Officer
Liz Dixon, Finance Director
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
finnCap Tel: 020 7220 0500
Geoff Nash/ Giles Rolls (Corporate Finance)
Alice Lane (ECM)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORUPGRAUUPUGAA

Talk to a Data Expert

Have a question? We'll get back to you promptly.